| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell, Tumor, and Stem Cell Biology |
-Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma1 Liver Carcinogenesis Section, Laboratory of Human Carcinogenesis, 2 Genetics Branch, Center for Cancer Research, and 3 Cancer Prevention Fellowship Program, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland; and 4 Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China
Requests for reprints: Xin Wei Wang, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Room 3044A, MSC 4258, Bethesda, MD 20892-4258. Phone: 301-496-2099; Fax: 301-496-0497; E-mail: xw3u{at}nih.gov.
Key Words: Hepatocellular carcinoma prognosis subtype EpCAM Cancer Stem cell
The heterogeneous nature of hepatocellular carcinoma (HCC) and the lack of appropriate biomarkers have hampered patient prognosis and treatment stratification. Recently, we have identified that a hepatic stem cell marker, epithelial cell adhesion molecule (EpCAM), may serve as an early biomarker of HCC because its expression is highly elevated in premalignant hepatic tissues and in a subset of HCC. In this study, we aimed to identify novel HCC subtypes that resemble certain stages of liver lineages by searching for EpCAM-coexpressed genes. A unique signature of EpCAM-positive HCCs was identified by cDNA microarray analysis of 40 HCC cases and validated by oligonucleotide microarray analysis of 238 independent HCC cases, which was further confirmed by immunohistochemical analysis of an additional 101 HCC cases. EpCAM-positive HCC displayed a distinct molecular signature with features of hepatic progenitor cells including the presence of known stem/progenitor markers such as cytokeratin 19, c-Kit, EpCAM, and activated Wnt-β-catenin signaling, whereas EpCAM-negative HCC displayed genes with features of mature hepatocytes. Moreover, EpCAM-positive and EpCAM-negative HCC could be further subclassified into four groups with prognostic implication by determining the level of
-fetoprotein (AFP). These four subtypes displayed distinct gene expression patterns with features resembling certain stages of hepatic lineages. Taken together, we proposed an easy classification system defined by EpCAM and AFP to reveal HCC subtypes similar to hepatic cell maturation lineages, which may enable prognostic stratification and assessment of HCC patients with adjuvant therapy and provide new insights into the potential cellular origin of HCC and its activated molecular pathways. [Cancer Res 2008;68(5):1451–61]
This article has been cited by other articles:
![]() |
J. Ji, J. Shi, A. Budhu, Z. Yu, M. Forgues, S. Roessler, S. Ambs, Y. Chen, P. S. Meltzer, C. M. Croce, et al. MicroRNA Expression, Survival, and Response to Interferon in Liver Cancer N. Engl. J. Med., October 8, 2009; 361(15): 1437 - 1447. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hoshida, S. M.B. Nijman, M. Kobayashi, J. A. Chan, J.-P. Brunet, D. Y. Chiang, A. Villanueva, P. Newell, K. Ikeda, M. Hashimoto, et al. Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma Cancer Res., September 15, 2009; 69(18): 7385 - 7392. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Dong, A. S. Budhu, and X. W. Wang Translating the Metastasis Paradigm from Scientific Theory to Clinical Oncology Clin. Cancer Res., April 15, 2009; 15(8): 2588 - 2593. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Pei, T. Zhang, V. Renault, and X. Zhang An overview of hepatocellular carcinoma study by omics-based methods Acta Biochim Biophys Sin, January 1, 2009; 41(1): 1 - 15. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Y. Chiang, A. Villanueva, Y. Hoshida, J. Peix, P. Newell, B. Minguez, A. C. LeBlanc, D. J. Donovan, S. N. Thung, M. Sole, et al. Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma Cancer Res., August 15, 2008; 68(16): 6779 - 6788. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sell and H. L. Leffert Liver Cancer Stem Cells J. Clin. Oncol., June 10, 2008; 26(17): 2800 - 2805. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |